MarketCap
Champions Oncology CSBR
€ 4.32
0.84%
Facebook
X
Telegram
Champions Oncology Betriebsaufwand | CSBR
Betriebsaufwand Jährlich Champions Oncology
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 12.5 M | 11 M | 12.5 M | 12.8 M | 14.5 M | 11.5 M | 9.22 M | 11.3 M | 8.98 M | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 14.5 M | 8.98 M | 11.6 M |
Betriebsaufwand Vierteljährlich Champions Oncology
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.58 M | - | - | - | 6.8 M | 7.33 M | 14.7 M | - | 5.15 M | 6.42 M | 6.42 M | 5.74 M | 4.97 M | 5.27 M | 5.27 M | 5.65 M | 4.92 M | 4.95 M | 4.95 M | 6.19 M | 5.25 M | 5.46 M | 5.46 M | 5.72 M | 5.1 M | 5.55 M | 5.55 M | 5.64 M | 3.64 M | 4.08 M | 4.08 M | 3.79 M | 4.17 M | 3.37 M | 3.37 M | 3.7 M | 3.59 M | 4.21 M | 4.21 M | 3.85 M |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 14.7 M | 3.37 M | 5.36 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M |  USA |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
84 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
12 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
26.7 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
66.9 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
18.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
9.17 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
32.3 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
3.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
8.75 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
343 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
104 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
47.2 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
345 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
36.8 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
528 M | - | - | $ 4.47 B | USA |
|
Frequency Therapeutics
FREQ
|
128 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
211 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
163 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
23.1 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
17.1 M | - | 1.35 % | $ 17.8 M |  China |
 |
Hepion Pharmaceuticals
HEPA
|
4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
12.4 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
120 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
161 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
30.2 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
59.1 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
5.11 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
180 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
8.44 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
13.7 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
53.4 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
20.7 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
156 M | - | - | $ 1.2 B |  Australia |
|
BiomX
PHGE
|
376 K | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
38.6 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
20.5 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
29.5 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
13.2 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
2.16 M | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
95.4 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
146 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
161 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
12.6 M | - | - | $ 2.64 M | USA |